Cannabinoids and Neuropsychiatric Disorders / edited by Eric Murillo-Rodriguez, S. R. Pandi-Perumal, Jaime M. Monti

Contributor(s):

Resource type: Ressourcentyp: Buch (Online)Book (Online)Language: English Series: Advances in Experimental Medicine and Biology ; 1264 | Springer eBook CollectionPublisher: Cham : Springer International Publishing, 2021Publisher: Cham : Imprint: Springer, 2021Edition: 1st ed. 2021Description: 1 Online-Ressource(XVII, 153 p. 43 illus., 4 illus. in color.)ISBN:

9783030573690

Subject(s):

611.01816 23

DOI: DOI: 10.1007/978-3-030-57369-0Online resources:

Summary: This volume highlights the recent advances in the understanding of the endocannabinoid system and the likely benefit from the therapeutic effects of cannabinoid treatment in a variety of health issues. Archeological evidence has shown that Cannabis has a long history of use for multiple purposes, including the treatment of medical conditions. The primary active constituent of the hemp plant Cannabis sativa, delta 9-tetrahydrocannabinol (Δ9-THC), causes euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concentration and impairment of memory, among other effects. Despite these undesirable effects, signaling is mostly inhibitory and suggests a putative role for cannabinoids as therapeutic agents by managing several diseases where inhibition of neurotransmitter release would be beneficial. The themes of this book have been edited and written by world-leaders in the field, The contents of the volume aims at readers from a range of academic and professional disciplines, such as biomedicine, several areas of biology, neurology, clinical medicine and pharmacy.PPN: PPN: 1743797052Package identifier: Produktsigel: ZDB-2-SBL | ZDB-2-SXB | ZDB-2-SEB

Holdings ( 0 )

No physical items for this record